David Dingli MD PhD, FRCP, FRCPEd, FACP, CBiol, FRSB

PubMed

• Clinical Outcomes and Treatment Strategies of Adult Transplant-Associated Thrombotic Microangiopathy: External Validation of Harmonizing Definitions and High-Risk Crit...
  Aldo A Acosta-Medina, Meera Sridharan, Ronald S Go, Ann M Moyer, Nelson Leung
  American Journal of Hematology. 2025-05-01
• Anchored Indirect Treatment Comparison Finds Comparable Effects of Pegcetacoplan and Iptacopan in Paroxysmal Nocturnal Haemoglobinuria.
  Regis Peffault de Latour, Austin Kulasekararaj, David Dingli, Koo Wilson, Piotr Wojciechowski
  European Journal of Haematology. 2025-04-25
• Coronary Artery Calcification As a Predictor of Survival in Patients Receiving Post-transplant Cyclophosphamide For GVHD Prophylaxis.
  Christopher Graham, Anmol Baranwal, Bas Kietselaer, Chadi Ayoub, Carolyn Larsen
  Transplantation and Cellular Therapy. 2025-04-24

Journal Articles

• Safety and Efficacy of Propylene Glycol-Free Melphalan as Conditioning in Patients with AL Amyloidosis Undergoing Stem Cell Transplantation  
  Nelson Leung, Prashant Kapoor, Taxiarchis V Kourelis, Eli Muchtar, Angela Dispenzieri, M Hasib Sidiqi, Martha Q Lacy, Wilson I Gonsalves, Shaji K Kumar, Mohammed A Alj..., Nature
• Relapse After Complete Response in Newly Diagnosed Multiple Myeloma: Implications of Duration of Response and Patterns of Relapse  
  Angela Dispenzieri, Francis K Buadi, Morie A Gertz, Martha Q Lacy, Nelson Leung, Amie L Fonder, Wilson I Gonsalves, Yi Lisa Hwa, Taxiarchis Kourelis, Surbhi Sidana, Ro..., Nature
• Primary Systemic Amyloidosis in Patients with Waldenström Macroglobulinemia  
  Angela Dispenzieri, Eli Muchtar, Ronald Go, Saurabh Zanwar, Surbhi Sidana, Francis Buadi, Stephen M Ansell, Prashant Kapoor, David Dingli, Thomas Habermann, Shaji Kuma..., Nature
• Daratumumab-Based Therapy in Patients with Heavily-Pretreated AL Amyloidosis  
  Saurabh Zanwar, Angela Dispenzieri, Wilson Gonsalves, David Dingli, Jithma P Abeykoon, Martha Q Lacy, Shaji Kumar, Nelson Leung, Morie A Gertz, Eli Muchtar, Francis Bu..., Nature
• Optimizing Deep Response Assessment for AL Amyloidosis Using Involved Free Light Chain Level at End of Therapy: Failure of the Serum Free Light Chain Ratio  
  Morie A Gertz, David Dingli, Miriam Hobbs, John A Lust, Ronald S Go, Amie Fonder, Yi Lin, Shaji K Kumar, Prashant Kapoor, Taxiarchis V Kourelis, S Vincent Rajkumar, Ro..., Nature
• Comparable Outcomes Using Propylene Glycol-Free Melphalan for Autologous Stem Cell Transplantation in Multiple Myeloma  
  Morie A Gertz, Shaji K Kumar, Martha Q Lacy, Prashant Kapoor, Suzanne R Hayman, Robert C Wolf, William J Hogan, Wilson I Gonsalves, Angela A Dispenzieri, David Dingli,..., Nature
• Utilization of Hematopoietic Stem Cell Transplantation for the Treatment of Multiple Myeloma: A Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) Consen...  
  John A Lust, Shaji K Kumar, Morie A Gertz, P Leif Bergsagel, Angela Dispenzieri, Francis K Buadi, Prashant Kapoor, Angela A Mayo, Wilson I Gonsalves, Rafael Fonseca, R..., Nature
• Join now to see all

Abstracts/Posters

• Waldenstr_m Macroglobulinemia with Excess Plasma Cells: Is It a Distinct Entity?
  David Dingli, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Peak Lymphocyte Count after CAR T Infusion Is a Clinically Accessible Test That Correlates with Clinical Response in Axicabtagene Ciloleucel Therapy for Lymphoma
  David Dingli, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• A Prospective Pilot Study of Ixazomib, Lenalidomide, and Dexamethasone for Patients with Newly Diagnosed or Relapsed/Refractory POEMS Syndrome
  David Dingli, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Influence of Cytogenetics in Patients with Relapsed Refractory Multiple Myeloma Treated with Oral Selinexor and Dexamethasone: A Post-Hoc Analysis of the STORM Study
  David Dingli, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• The Impact of Socioeconomic Risk Factors on the Survival Outcomes of Patients with Newly Diagnosed Multiple Myeloma
  David Dingli, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Impact of sFLC Ratio on Outcome in Patients with MM: Validating the Utility of sFLC in Response Definition
  David Dingli, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Utilizing Multiparametric Flow Cytometry to Identify Patients with Primary Plasma Cell Leukemia at Diagnosis
  David Dingli, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Use of Maintenance Therapy Post Autologous Stem Cell Transplantation Outside of Clinical Trial Setting for Multiple Myeloma: Single Institution Experience
  David Dingli, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Mortality of Patients with Multiple Myeloma after the Introduction of Novel Therapies in the United States
  David Dingli, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Phase 2 Trial of Daratumumab, Ixazomib, Lenalidomide and Modified Dose Dexamethasone in Patients with Newly Diagnosed Multiple Myeloma
  David Dingli, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Prognostic Implications of Serum Monoclonal Protein Positivity By Mass-Fix in Bone Marrow Minimal Residual Disease Negative (MRD-) Patients with Multiple Myeloma
  David Dingli, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• A Novel Approach to Risk Stratification in Multiple Myeloma Using ISS Stage and FISH
  David Dingli, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Delayed Neutrophil Engraftment in Patients Receiving Daratumumab As Part of Their First Induction Regimen for Multiple Myeloma
  David Dingli, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Response to Therapy and the Effectiveness of Treatment with Selinexor and Dexamethasone in Patients with Penta-Exposed Triple-Class Refractory Myeloma Who Had Plasmacy...
  David Dingli, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Optimal Therapy for Relapsed AL Amyloidosis Post Autologous Stem Cell Transplant
  David Dingli, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Join now to see all

Lectures

• Ibrutinib Therapy in Patients with Waldenstrom Macroglobulinemia: Outcomes Outside of Clinical Trial Setting 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Bortezomib, Lenalidomide and Dexamethasone (VRD) Followed By Autologous Stem Cell Transplant for Newly Diagnosed Multiple Myeloma; The Mayo Clinic Experience 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Prognostic Value of Clone Size in Paroxysmal Nocturnal Hemoglobinuria (PNH) for Thrombotic Events in Untreated Patients in the International PNH Registry 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Long-Term Survivorship with Active Multiple Myeloma 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Join now to see all